Influenza A Market to Witness Robust Expansion at a CAGR of 8.5% in the United States During the Study Period (2019-2032), Assesses DelveInsight

News provided by

Jan 10, 2023, 10:30 ET

The influenza A market is expected to surge in the coming years as the emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action for the treatment of patients affected with influenza A infections. At a global level, some key players in the influenza A market are Sanofi, AstraZeneca, GSK, and others.

LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- DelveInsight's Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Influenza A Market Report

As per DelveInsight analysis, the influenza A market size in the US was approximately USD 3.6 billion in 2021
According to the assessment done by DelveInsight, the total vaccinated pool of influenza A in the United States was approximately 176 million in 2021
Leading influenza A companies such as Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Genentech, Roche, BioCryst Pharmaceuticals, Sanofi, AstraZeneca, Seqirus, GSK, and others are developing novel influenza A drugs that can be available in the influenza A market in the coming years
The promising influenza A therapies/vaccines in the pipeline include CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
The increase in influenza A market size is a direct consequence of an increase in R&D activity, increasing prevalent population, and the expected commercial success of upcoming therapies.
In September 2022, Cidara Therapeutics announced the initiation of its Phase IIa trial to evaluate the pre-exposure prophylactic activity of CD388 against the influenza virus
In April 2021, Cidara Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza

Discover which therapies are expected to grab the major influenza A market share @ Influenza A Market Report

Influenza A Overview

Influenza is an acute viral respiratory disease caused by respiratory tract infection with influenza viruses (seasonal influenza A and B viruses) that circulate worldwide. Unlike annual seasonal epidemics, sporadic pandemic outbreaks are caused by zoonotic influenza A virus strains.

Symptoms of influenza virus infection range from mild upper respiratory disease characterized by fever, sore throat, runny nose, cough, headache, muscle pain, and fatigue to severe and, in some cases, lethal pneumonia caused by influenza virus or secondary bacterial infection of the lower respiratory tract.

The clinical presentation and epidemiological likelihood of infection are used to make an influenza A diagnosis. Nonspecific influenza A symptoms, such as fever, chills, frank shaking, headaches, myalgia, malaise, and anorexia, predominate at first. These influenza A symptoms usually appear suddenly, and respiratory symptoms, such as a dry cough, sore or dry throat, nasal obstruction, and discharge, are also present.

Influenza A Epidemiology Segmentation

DelveInsight estimates that the total influenza A positive cases in the United States comprised approximately 42.5K cases in 2021 and are projected to increase during the study period.

In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, and 35,156 cases in 2021.

The influenza A market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Vaccinated Pool of Influenza A
Influenza A Positive Cases
Strain-specific Cases of Influenza A (2019–2022)

Download the report to understand which factors are driving influenza A epidemiology trends @ Influenza A Epidemiological Insights

Influenza A Treatment Market

Early antiviral intervention can benefit public health by improving clinical outcomes for patients at high risk of influenza-related complications, as well as potentially saving patients and the healthcare system money. MedImmune introduced the first licensed live attenuated influenza virus vaccine (LAIV) in the United States in 2003. This vaccine is based on the influenza A/Ann Arbor/6/1960 backbones. LAIVs appear to be more effective than inactivated influenza virus preparations at inducing mucosal and broadly protective immune responses in infants and children. However, studies in the United States with LAIVs have revealed poor efficacy against influenza A H1N1 component1.

Another breakthrough for influenza vaccines occurred in 2013 when the FDA approved FLUZONE QUADRIVALENT, a product made entirely of recombinant DNA technologies. Antiviral drugs, in conjunction with vaccines, are critical in preventing and treating influenza virus infection and disease. During a typical influenza season, antiviral drugs are primarily used to treat severely ill patients, particularly those with a compromised immune system. TAMIFLU, RELENZA, and RAPIVAB are approved therapies that work by mimicking sialic acid binding in the active site of NA on influenza A and B viruses.

To know more about influenza A guidelines, visit @ Influenza A Treatment Options

Influenza A Pipeline Therapies/Vaccines and Key Companies

CD388: Cidara Therapeutics
SAB-176: SAb Biotherapeutics
M2SR: FluGen
mRNA-1010: Moderna
VIR-2482: Vir Biotechnology
VXA-A1.1: Vaxart

Learn more about the FDA-approved influenza A drugs @ Drugs for Influenza A Treatment

Influenza A Market Dynamics

The dynamics of the influenza A market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Moreover, the presence of a large number of manufacturers contributes to the influenza A market growth. Furthermore, key players are heavily investing in research activities to broaden the therapeutic application of treatment drugs, thereby expanding the scope and opportunities for the treatment, thereby boosting the influenza A market growth.

However, certain factors act as barriers and affect the influenza A market growth. The inadequate epidemiological data availability of patient care reference centers is among the prominent factors hampering the growth of the influenza A market. Moreover, the global influenza A market is fragmented, owing to the presence of several major players. Furthermore, payers and insurance companies will attempt to limit the use of drugs with mediocre efficacy but high prices, thus leading to a dip in the growth of the influenza A market. Hence, all these factors mentioned above are likely to impede the influenza A market growth in the future.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year	2019
Influenza A Market CAGR (in the US)	8.5 %
Influenza A Market Size in 2021 (in the US)	USD 3.6 billion
Key Influenza A Companies	Sanofi, AstraZeneca, Seqirus, GSK, Roche, Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Genentech, Roche, BioCryst Pharmaceuticals, Sanofi, AstraZeneca, Seqirus, GSK, and others
Key Pipeline Influenza A Therapies/Vaccines	CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, VXA-A1.1, and others

Scope of the Influenza A Market Report

Therapeutic Assessment: Influenza A current marketed and emerging therapies
Influenza A Market Dynamics: Influenza A market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Influenza A Market Access and Reimbursement

Discover more about influenza A drugs in development @ Influenza A Clinical Trials

Table of Contents

1.	Influenza A Market Key Insights
2.	Influenza A Market Report Introduction
3.	Influenza A Market Executive Summary
4.	Influenza A Key Events
5.	Epidemiology and Market Methodology
6.	Influenza A Market Overview at a Glance
7.	Influenza A Disease Background and Overview
8.	Influenza A Treatment and Management
9.	Influenza A Epidemiology and Patient Population in the 7MM
9.1	Key Findings
9.2	Assumptions and Rationale
9.3	Total Vaccinated Pool of Influenza A in the 7MM
9.4	United States
9.5	EU-4 and the UK
9.6	Japan
10	Patient Journey
11	Key Endpoints in Influenza A
12	Influenza A Marketed Vaccines and Drugs
13	Influenza A Emerging Vaccines and Drugs
13.1	Seven Major Influenza A Market Analysis
13.2	Key Findings
13.3	Market Outlook
13.4	Key Market Forecast Assumptions
13.5	Total Market size of Influenza A in the 7MM
13.6	United States Market Size
13.7	EU-4 and the UK Market Size
13.8	Japan Market Size
14	Market Access And Reimbursement
15	SWOT Analysis
16	Unmet Needs
17	Appendix
18	DelveInsight Capabilities
19	Disclaimer
20	About DelveInsight

Related Reports

Influenza A Epidemiology Forecast

Influenza A Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted influenza A epidemiology in the 7MM, i.e., the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Influenza A Infections Pipeline

Influenza A Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A infections companies, including Janssen Research & Development, LLC, Immune Targeting Systems Ltd, Vir Biotechnology, Inc., Guangdong Raynovent Biotech Co., Ltd, Hualan Biological Bacterin Co. Ltd., Celltrion, among others.

Influenza B Infections Pipeline

Influenza B Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza B infections companies, including Leyden Labs, Nanjing Zenshine Pharmaceuticals, SAB Biotherapeutics, among others.

Influenza Pipeline

Influenza Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osiva, among others.

Seasonal Influenza Market

Seasonal Influenza Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key seasonal influenza companies, including SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., among others.

Influenza A Virus H5N1 Subtype Pipeline

Influenza A Virus H5N1 Subtype Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A virus H5N1 subtype companies, including Protein Sciences, Altimmune, Vaxart, Greffex, Cocrystal Pharma, among others.

Other Trending Reports

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP